Hepaticocholecystojejunostomy as effective palliative biliary bypass for unresectable pancreatic cancer.

Junji Ueda, Tadashi Kayashima, Yasuhisa Mori, Ohtsuka Takao, Shunich Takahata, Masafumi Nakamura, Masao Tanaka

研究成果: ジャーナルへの寄稿記事

6 引用 (Scopus)

抄録

The majority of patients with pancreatic cancer present with far advanced disease and jaundice. With the advancement of endoscopic interventional techniques, the role of surgical bypass has declined. However, surgical bypass is still considered to be appropriate in patients who are able to tolerate surgery. We performed hepaticocholecystojejunostomy consecutively as a palliative surgical biliary bypass for the purpose of long-term palliation. The aim of this study was to analyze the results of our palliative surgical biliary bypass, hepaticocholecystojejunostomy. Between January 2001 through December 2009, 69 patients received palliative surgical biliary bypass (bypass group) and 33 patients received endoscopic biliary stenting (stent group) for unresectable pancreatic cancers. Mortality, morbidity and survival between the two groups were compared. There was no in-hospital death in the bypass group, but 2 patients (6%) in the stent group died in the hospital (p = 0.04). The surgical morbidity rate was 15% in the bypass group, while 20 patients (61%) in the stent group developed complications, mainly due to stent blockage. There was no significant difference in overall survival between the two groups. Among patients who underwent systemic chemotherapy but did not present with jaundice at the time of diagnosis, those who underwent prophylactic surgical biliary bypass before chemotherapy showed better survival than those who underwent systemic chemotherapy preceding biliary bypass or biliary stenting after occurrence of jaundice (p = 0.01). Hepaticocholecystojejunostomy resulted in negligible mortality, low morbidity and effective long-term palliation. Prophylactic surgical biliary bypass with gastrointestinal bypass might be a good treatment option for non-jaundiced patients undergoing chemotherapy for unresectable pancreatic cancer.

元の言語英語
ページ(範囲)197-202
ページ数6
ジャーナルHepato-Gastroenterology
61
発行部数129
出版物ステータス出版済み - 1 1 2014

Fingerprint

Pancreatic Neoplasms
Stents
Jaundice
Drug Therapy
Morbidity
Survival
Mortality

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

これを引用

Hepaticocholecystojejunostomy as effective palliative biliary bypass for unresectable pancreatic cancer. / Ueda, Junji; Kayashima, Tadashi; Mori, Yasuhisa; Takao, Ohtsuka; Takahata, Shunich; Nakamura, Masafumi; Tanaka, Masao.

:: Hepato-Gastroenterology, 巻 61, 番号 129, 01.01.2014, p. 197-202.

研究成果: ジャーナルへの寄稿記事

@article{4570f39c931d40f081433a9ec6ad688e,
title = "Hepaticocholecystojejunostomy as effective palliative biliary bypass for unresectable pancreatic cancer.",
abstract = "The majority of patients with pancreatic cancer present with far advanced disease and jaundice. With the advancement of endoscopic interventional techniques, the role of surgical bypass has declined. However, surgical bypass is still considered to be appropriate in patients who are able to tolerate surgery. We performed hepaticocholecystojejunostomy consecutively as a palliative surgical biliary bypass for the purpose of long-term palliation. The aim of this study was to analyze the results of our palliative surgical biliary bypass, hepaticocholecystojejunostomy. Between January 2001 through December 2009, 69 patients received palliative surgical biliary bypass (bypass group) and 33 patients received endoscopic biliary stenting (stent group) for unresectable pancreatic cancers. Mortality, morbidity and survival between the two groups were compared. There was no in-hospital death in the bypass group, but 2 patients (6{\%}) in the stent group died in the hospital (p = 0.04). The surgical morbidity rate was 15{\%} in the bypass group, while 20 patients (61{\%}) in the stent group developed complications, mainly due to stent blockage. There was no significant difference in overall survival between the two groups. Among patients who underwent systemic chemotherapy but did not present with jaundice at the time of diagnosis, those who underwent prophylactic surgical biliary bypass before chemotherapy showed better survival than those who underwent systemic chemotherapy preceding biliary bypass or biliary stenting after occurrence of jaundice (p = 0.01). Hepaticocholecystojejunostomy resulted in negligible mortality, low morbidity and effective long-term palliation. Prophylactic surgical biliary bypass with gastrointestinal bypass might be a good treatment option for non-jaundiced patients undergoing chemotherapy for unresectable pancreatic cancer.",
author = "Junji Ueda and Tadashi Kayashima and Yasuhisa Mori and Ohtsuka Takao and Shunich Takahata and Masafumi Nakamura and Masao Tanaka",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "61",
pages = "197--202",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "129",

}

TY - JOUR

T1 - Hepaticocholecystojejunostomy as effective palliative biliary bypass for unresectable pancreatic cancer.

AU - Ueda, Junji

AU - Kayashima, Tadashi

AU - Mori, Yasuhisa

AU - Takao, Ohtsuka

AU - Takahata, Shunich

AU - Nakamura, Masafumi

AU - Tanaka, Masao

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The majority of patients with pancreatic cancer present with far advanced disease and jaundice. With the advancement of endoscopic interventional techniques, the role of surgical bypass has declined. However, surgical bypass is still considered to be appropriate in patients who are able to tolerate surgery. We performed hepaticocholecystojejunostomy consecutively as a palliative surgical biliary bypass for the purpose of long-term palliation. The aim of this study was to analyze the results of our palliative surgical biliary bypass, hepaticocholecystojejunostomy. Between January 2001 through December 2009, 69 patients received palliative surgical biliary bypass (bypass group) and 33 patients received endoscopic biliary stenting (stent group) for unresectable pancreatic cancers. Mortality, morbidity and survival between the two groups were compared. There was no in-hospital death in the bypass group, but 2 patients (6%) in the stent group died in the hospital (p = 0.04). The surgical morbidity rate was 15% in the bypass group, while 20 patients (61%) in the stent group developed complications, mainly due to stent blockage. There was no significant difference in overall survival between the two groups. Among patients who underwent systemic chemotherapy but did not present with jaundice at the time of diagnosis, those who underwent prophylactic surgical biliary bypass before chemotherapy showed better survival than those who underwent systemic chemotherapy preceding biliary bypass or biliary stenting after occurrence of jaundice (p = 0.01). Hepaticocholecystojejunostomy resulted in negligible mortality, low morbidity and effective long-term palliation. Prophylactic surgical biliary bypass with gastrointestinal bypass might be a good treatment option for non-jaundiced patients undergoing chemotherapy for unresectable pancreatic cancer.

AB - The majority of patients with pancreatic cancer present with far advanced disease and jaundice. With the advancement of endoscopic interventional techniques, the role of surgical bypass has declined. However, surgical bypass is still considered to be appropriate in patients who are able to tolerate surgery. We performed hepaticocholecystojejunostomy consecutively as a palliative surgical biliary bypass for the purpose of long-term palliation. The aim of this study was to analyze the results of our palliative surgical biliary bypass, hepaticocholecystojejunostomy. Between January 2001 through December 2009, 69 patients received palliative surgical biliary bypass (bypass group) and 33 patients received endoscopic biliary stenting (stent group) for unresectable pancreatic cancers. Mortality, morbidity and survival between the two groups were compared. There was no in-hospital death in the bypass group, but 2 patients (6%) in the stent group died in the hospital (p = 0.04). The surgical morbidity rate was 15% in the bypass group, while 20 patients (61%) in the stent group developed complications, mainly due to stent blockage. There was no significant difference in overall survival between the two groups. Among patients who underwent systemic chemotherapy but did not present with jaundice at the time of diagnosis, those who underwent prophylactic surgical biliary bypass before chemotherapy showed better survival than those who underwent systemic chemotherapy preceding biliary bypass or biliary stenting after occurrence of jaundice (p = 0.01). Hepaticocholecystojejunostomy resulted in negligible mortality, low morbidity and effective long-term palliation. Prophylactic surgical biliary bypass with gastrointestinal bypass might be a good treatment option for non-jaundiced patients undergoing chemotherapy for unresectable pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84902651315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902651315&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 197

EP - 202

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 129

ER -